AMB-018(AMB-018) - 在研适应症：实体瘤_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

靶点-

作用机制

巨噬细胞抑制剂

治疗领域

肿瘤

在研适应症

实体瘤

非在研适应症-

原研机构

AimedBio, Inc.

在研机构

AimedBio, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 AMB-018 相关的临床结果

登录后查看更多信息

100 项与 AMB-018 相关的转化医学

登录后查看更多信息

100 项与 AMB-018 相关的专利（医药）

登录后查看更多信息

1

项与 AMB-018 相关的文献（医药）

2008-06-01·The Journal of Antibiotics4区 · 医学

Efrapeptin J, a New Down-regulator of the Molecular Chaperone GRP78 from a Marine Tolypocladium sp.

4区 · 医学

Article

作者: Kaneo Kanoh ; Yuki Hattori ; Yoshikazu Shizuri ; Yoichi Hayakawa ; Kazuo Shin-ya ; Takashi Kawasaki ; Kyoko Adachi

A new down-regulator of the molecular chaperone GRP78, efrapeptin J, was isolated from a marine fungus, Tolypocladium sp. AMB18. The molecular formula of efrapeptin J was established as C(81)H(139)N(18)O(16)(+) by high-resolution FAB-MS. The structure was elucidated to be a linear pentadecapeptide containing a hexahydropyrrolo[1,2-a]pyrimidinium moiety by NMR and MS analyses. Efrapeptins F, G and J dose-dependently inhibited 2-deoxyglucose-induced luciferase expression in HT1080 human fibrosarcoma cells transfected with a luciferase reporter plasmid containing the GRP78 promoter. Efrapeptin J also inhibited the protein expression of GRP78 in HT1080 cells and MKN-74 human gastric cancer cells. Efrapeptin J induced cell death in HT1080 cells under endoplasmic reticulum stress.

100 项与 AMB-018 相关的药物交易

登录后查看更多信息